Objective: The aim of this study was to determine the factors associated with the prognosis of newborns born to mothers with idiopathic thrombocytopenic purpura (ITP), and to compare the infants with/without thrombocytopenia in terms of maternal and neonatal characteristics.
Introduction
Idiopathic thrombocytopenic purpura (ITP) is an autoimmune disorder of adults and children in which the patient's platelets are destroyed by autoantibodies. 1, 2 It is most common in young women during childbearing age and may be associated with maternal and fetal complications. 2 Although older studies reported a high perinatal mortality rate (12 to 21%), such has not been confirmed for neonatal outcomes. In addition, it is widely accepted that the frequency of intracranial hemorrhage is very rare, affecting 0 to 1% at-risk babies. [3] [4] [5] However, severe thrombocytopenia (<20 Â 10 9 per liter) in neonates born to mothers with ITP has been reported in 3 to 5% of cases. 6, 7 Although several studies have been designed to define maternal characteristics for predicting the platelet level of newborns, no correlation has been shown between neonatal thrombocytopenia (NT) and the maternal platelet count, a history of earlier splenectomy or maternal platelet antibodies. Hence, it was suggested that a history of previous NT and the severity of maternal disease might be reliable predictors of NT. [8] [9] [10] As only limited and conflicting data are available on the effect of maternal ITP on neonatal outcomes, we aimed to determine the factors associated with prognosis in newborns born to gravidas with ITP during pregnancy and also to compare the infants with and without thrombocytopenia in terms of maternal and neonatal characteristics.
Methods
All of the pregnant women that were followed up and treated by Hematology Department of Uludag University School Medicine Hospital in Bursa, Turkey were identified. A retrospective chart review was performed for all obstetric patients with ITP who were treated and delivered between 1 January 1998 and 31 December 2008. At the same time, a similar chart review was performed for the infants born to these mothers with ITP. During the study interval, 38 gravidas with ITP delivered 38 neonates in 38 pregnancies; however, 9 pregnancies were excluded due to insufficient maternal data. Therefore, a total of 29 gravidas and their infants were included in this study. Inclusion criteria were a diagnosis of ITP during pregnancy or a pregnancy with a previous history of ITP. Infants born to mothers with other autoimmune diseases (for example, systemic lupus erythematosus), preeclampsia and hemolytic anemio, elevated liver enzymes, low platelet count syndrome were excluded. Infants with other causes of NT, such as sepsis, perinatal asphyxia, disseminated intravascular coagulation, drug-induced thrombocytopenia and hereditary forms of thrombocytopenia were also excluded.
Maternal evaluation ITP was diagnosed using standard criteria: (1) thrombocytopenia >6 months, (2) a normal bone marrow examination, (3) a normal white and red blood cell count and (4) exclusion of other causes of thrombocytopenia.
The maternal platelet count was determined every 3 weeks from the time of diagnosis in pregnancy to delivery (more frequently in cases of severe thrombocytopenia). Platelet counts were performed in blood samples collected in tubes containing ethylenediamine tetraacetate using an automated cell counter Cell-Dyn 3700 (Abbott Diagnostics, Abbott Park, IL, USA). In each case, pseudothrombocytopenia was excluded by examining a peripheral blood smear.
A normal platelet count was defined as >150 Â 10 9 per liter, mild thrombocytopenia was defined as a platelet count of 100 to 150 Â 10 9 per liter, moderate thrombocytopenia was defined as a platelet count of 50 to 99 Â 10 9 per liter, and severe thrombocytopenia was defined as a platelet count of <50 Â 10 9 per liter. Maternal circulating antiplatelet antibodies were detected by an indirect immunofluorescence test (IFT Euroimmun, Lü beck, Germany).
Patients with a platelet count <50 Â 10 9 per liter or those with significant signs of bleeding were given treatment at the time of initial diagnosis. Patients who had an indication for treatment were usually given prednisone (1 mg kg À1 day À1 p.o. for 3 to 4 weeks). When a normal platelet count was achieved, steroids were tapered within several weeks. Intravenous immunoglobulin (IVIG) was used at a dose of 0.4 g kg À1 day À1 for 5 consecutive days every 28 days for two cycles. Splenectomy was performed on patients refractory to steroids or those who became steroid-dependent to maintain remission, as well as on those who failed to respond to IVIG therapy. Informed consent was obtained in each case.
Neonatal evaluation
Neonatal passive immune thrombocytopenia was defined as thrombocytopenia with a platelet count <150 Â 10 9 per liter in infants born to gravidas with ITP. Mild thrombocytopenia was defined as a platelet count of 100 to 150 Â 10 9 per liter, moderate thrombocytopenia as a platelet count of 50 to 99 Â 10 9 per liter and severe thrombocytopenia as a platelet count of <50 Â 109 per liter.
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A cord blood platelet count was performed at birth for all newborns born to gravidas with ITP (the same technique as in the gravidas), followed by a platelet count by venipuncture on days 1, 3 and 5. All infants were evaluated for mucosal bleeding (petechiae and ecchymoses), gastrointestinal or intracranial hemorrhage. For determining intracranial hemorrhage, cranial ultrasonography was performed by the same pediatric radiologist in all the 14 thrombocytopenic infants when thrombocytopenia was detected. It was also repeated weekly in the thrombocytopenic infants through the thrombocytopenia period. The platelet counts of all infants were evaluated through the first 3 months of life to determine the duration of postnatal thrombocytopenia. Data including gestational age, gender, birth weight, Apgar scores, mode of delivery, prematurity and the platelet count were recorded. Infants who had thrombocytopenia were compared with those who had normal platelet counts in terms of maternal and demographic features.
Neonates with a platelet count of <50 Â 10 9 per liter and/or bleeding symptoms were given IVIG with a dose of 1 g kg À1 day À1 for 2 days. Steroid therapy (prednisolone (2 mg kg À1 day À1 p.o.)) was given to cases who failed to respond to IVIG therapy. Packed red blood cells and platelet transfusions were administered if severe hemorrhage or severe anemia occurred due to bleeding.
Statistical analysis SPSS, version 16.0 (SPSS Inc., Chicago, IL, USA), was used for data analyses. Descriptive statistics were given as the mean, median, standard deviation, minimum, maximum and percentage. A w 2 -test was used for analysis of qualitative data. A non-parametric test was used for analysis of two independent quantitative variables.
Results
A total of 29 infants born to gravidas with ITP before or during pregnancy were included in this study. Table 1 summarizes the maternal and neonatal characteristics of 29 cases with ITP before or during pregnancy.
Maternal outcomes
A total of 16 gravidas (55%) were diagnosed with ITP before pregnancy and 13 gravidas (45%) were diagnosed with ITP during pregnancy. Thrombocytopenia existed in 21 gravidas (72%), whereas 8 gravidas had normal platelet counts at the time of delivery. Thrombocytopenia was classified as mild, moderate and severe in 2 (7%), 11 (38%) and 8 (27.5%) thrombocytopenic gravidas, respectively. Table 1 shows the maternal characteristics.
A total of 17 gravidas (59%) were administered corticosteroids because of very low platelet counts. High-dose immunoglobulin was administered to eight gravidas (27.5%). In total, nine gravidas (31%) were given platelet transfusions to increase their platelet counts. Splenectomies were performed in six gravidas (20%), and before pregnancy in four of the six. One patient underwent a splenectomy in the second trimester due to failure of corticosteroid and IVIG therapies.
No bleeding occurred in 27 gravidas (93%) during pregnancy or delivery. Epistaxis and mucosal bleeding were separately observed in two gravidas. Neither the vaginal route of delivery (72%) nor cesarean delivery (28%) led to excessive bleeding in gravidas. The mean platelet count at delivery was 133±125 Â 10 9 per liter. Table 1 shows the characteristics of the infants. The mean gestational age and birth weight of the infants were 38 ± 1.8 weeks (range, 34 to 40 weeks) and 3114±545 g (range, 2250 to 4450 g), respectively. Table 2 shows the characteristics of infants and gravidas with thrombocytopenia. Thrombocytopenia was classified as mild, moderate and severe in three (10.3%), four (13.7%), and seven (24.1%) thrombocytopenic neonates, respectively.
Neonatal outcomes
Severe hemorrhage occurred in five infants (17%). Generalized petechiae and ecchymoses with gastrointestinal bleeding were detected in two infants with severe thrombocytopenia, whereas mucosal bleeding occurred in three infants with moderate or severe thrombocytopenia.
Platelet and packed red cell transfusions were administered to two infants with gastrointestinal bleeding. No intraventricular hemorrhage was determined in infants. Thrombocytopenia persisted for an average of 13 ± 16 days (range, 4 to 60 days) in infants with thrombocytopenia. Thrombocytopenia lasted longer than 30 days in four infants, three of whom had mothers with positive antiplatelet antibodies and severe thrombocytopenia compared with the other mothers. Table 3 shows the maternal characteristics of infants with thrombocytopenia. Although three mothers had pregnancy onset ITP with negative autoantibodies and normal platelet counts at delivery, they had ITP diagnosis at the follow-up according to the diagnostic ITP criteria. They were also given appropriate therapies for ITP at the follow-up. Table 4 shows the comparison of characteristics of infants with and without thrombocytopenia. The age of the mothers having infants with thrombocytopenia was significantly higher, most of the infants (71%) were males (P<0.05).
Infants with and without thrombocytopenia were also compared with respect to maternal characteristics. Overall, 64% of mothers in the thrombocytopenic infant group and 46% of the mothers in the non-thrombocytopenic infant group were diagnosed with ITP (Table 5 , P>0.05). In total, 9 of 14 mothers (64%) with thrombocytopenic infants had a history of platelet transfusions during pregnancy, whereas 13% of mothers with nonthrombocytopenic infants required an antepartum platelet transfusion (Table 5 , P<0.05). Splenectomy before pregnancy was performed on four mothers in the thrombocytopenic infant group and one mother in the non-thrombocytopenic infant group. In addition, splenectomy was performed on one mother in the second trimester and this infant had thrombocytopenia at birth. There were no significant differences in terms of maternal splenectomy between the two groups of infants. The mean platelet counts of mothers at delivery were significantly lower in the thrombocytopenic infant group compared with those in the nonthrombocytopenic group (Table 5 , P<0.05).
A total of seven infants born to eight mothers with severe thrombocytopenia during delivery (87.5%) had thrombocytopenia Treatment, n (%) Intravenous immunoglobulin 11 (38) Corticosteroids 2 (7) Need of transfusion with packed red cell and/or platelet 2 (7) Mortality, n (%) 0 (0) Abbreviation: ITP, thrombocytopenic purpura.
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at birth (Table 6 , P<0.05). Table 6 shows the association between maternal platelet counts and infant platelet counts at birth.
Discussion
Neonatal thrombocytopenia secondary to transplacental passage of maternal platelet autoantibodies occurs in neonates born to gravidas with ITP or systemic lupus erythematosus. In this retrospective study, 48% of neonates born to gravidas with ITP had thrombocytopenia at birth. Maternal age and male gender were shown to be risk factors for the development of thrombocytopenia. Severe maternal thrombocytopenia, recurrence during pregnancy and platelet transfusion during pregnancy were also associated with thrombocytopenia in infants.
Maternal disease severity and/or platelet count during pregnancy or the occurrence of severe thrombocytopenia in a previous neonate have been reported as the most powerful indicators for predicting the likelihood of significant fetal and NT complicating the current pregnancy. 12 A recent retrospective study that included a high proportion of thrombocytopenic gravidas Outcomes of pregnancy complicated by ITP H Ö zkan et al showed a higher incidence of affected neonates, 25% of whom had thrombocytopenia, 9% of whom had a platelet count of <50 Â 10 9 per liter, 15% of whom received treatment for bleeding in association with thrombocytopenia and two fetuses died (one with extensive hemorrhage). 13 In other studies, development of severe thrombocytopenia (<50 Â 10 9 per liter) and more severe thrombocytopenia (<20 Â 10 9 per liter) in infants born to mothers with ITP were reported to be 6 to 10% and 1 to 5%, respectively. 9, 10, 14, 15 In our study, 50% of infants had platelet counts <150 Â 10 9 per liter. Rates of severe, moderate and mild thrombocytopenia were detected in 24, 14 and 10%, respectively. This finding was similar to a previous study performed in our institute, 16 and was consistent with the report of Nisaratanaporn and Sukcharoen, 17 who found that 24% of infants born to gravidas with ITP have severe thrombocytopenia at birth. Borna et al. 18 reported thrombocytopenia in 20 infants (67%) born to 30 gravidas with ITP and the ratio was also in good accord with the data reported in this study. On the other hand, conflicting data exist on the effect of severity of maternal thrombocytopenia on neonatal outcomes. In this study, 87.5% of infants born to gravidas with severe thrombocytopenia were thrombocytopenic at birth, with 70% having moderate or severe thrombocytopenia. However, 50% of infants born to gravidas with normal platelet counts during delivery also had thrombocytopenia at birth. Therefore, we suggest that the severity of thrombocytopenia during delivery may affect the neonatal platelet count and may be associated with the severity of NT. This hypothesis was supported by findings reported by Valat et al. 9 who detected severe thrombocytopenia at birth in 57% of infants who were born to gravidas with severe thrombocytopenia. Similarly, severe maternal thrombocytopenia has been suggested to be highly predictive of thrombocytopenia in infants. 19, 20 In contrast, some studies have reported no correlation between maternal and neonatal platelet counts. 9, 13, 21, 22 These differences may be due to the differences in number of patients, maternal and neonatal inclusion criteria, maternal and neonatal platelet evaluation time, lack of data and the potential of misdiagnosis.
Another important finding of this study was that male neonates born to gravidas with ITP had significantly more severe thrombocytopenia compared with female neonates. This finding is also consistent with the study of Mortensen et al. 20 who reported male gender as a risk factor for perinatal thrombocytopenia. As limited data are available on the effect of a neonate's gender on the risk of perinatal thrombocytopenia, further investigations are warranted.
We found in this study that maternal age is an important risk factor for severe thrombocytopenia in infants born to gravidas with ITP, as maternal age was significantly higher in infants with thrombocytopenia. Our study is the first to report data on the effect of maternal age on NT. Therefore, this subject should be validated in future studies.
Antiplatelet antibodies were positive in 55% of 29 gravidas. Boehlen et al. 23 suggested that antiplatelet antibodies were not associated with the severity of NT and that maternal antiplatelet antibodies could not be used for predicting the risk of NT. However, in our study, we found that thrombocytopenia persisted in infants Outcomes of pregnancy complicated by ITP H Ö zkan et al born to mothers with positive antiplatelet autoantibodies compared with those lacking these antibodies. Splenectomy was reported to be the single important risk factor for severe NT in one study, 21 which included 52 gravidas and 54 infants. A more recent and larger scale study from Japan including 284 gravidas with ITP and 286 neonates reported that infants born to splenectomized mothers had more severe thrombocytopenia compared with those born to mothers who had not undergone a splenectomy. 22 Although similar data have been found in this study, the difference was not statistically significant, likely due to the small sample size.
Corticosteroids with or without immunoglobulins were given to gravidas if indicated. Although infants born to gravidas who received neither steroids nor immunoglobulins had more severe thrombocytopenia, the difference was not statistically significant. This finding is also consistent with the literature. 22 NT was significantly higher in infants born to gravidas who had received a platelet infusion during pregnancy. Maternal history of recurrent ITP and bleeding during pregnancy were also associated with NT. As limited data are available on the effect of maternal features on the severity of NT, we suggest that all of these features may be associated with the severity of ITP in pregnancy and must be investigated in future studies.
The mode of delivery in gravidas with ITP is a controversial issue. It is generally accepted that neonates born to mothers with ITP may be delivered vaginally unless a cesarean delivery is indicated for obstetrical reasons. 1, 2, 13, 16, 24 In our study, eight gravidas (28%) underwent cesarean delivery for obstetrical indications and the remaining gravidas (72%) were delivered vaginally. No complications occured either in the mother or the fetus due to the route of delivery. This finding is also in good agreement with previous studies. 1, 6, 11, 13, 16, 25 Although 14 infants presented with thrombocytopenia (3 mild, 4 moderate and 7 severe) in this study, none of them had intracranial hemorrhages. This finding is also in good agreement with previous studies that reported a very low risk of 0 to 2% for severe thrombocytopenia intracranial bleeding.
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As a result, maternal age and male gender were the main risk factors associated with increased NT in infants born to mothers with ITP. Severe maternal disease, recurrence during pregnancy and platelet transfusion during pregnancy were also associated with severe NT. Infants born to mothers with severe ITP might have risks for NT and the duration of thrombocytopenia might be longer in infants born to mothers with positive antiplatelet antibodies. As these risk factors were not mentioned in previous studies, future prospective studies, including a higher number of gravidas and infants are warranted for reliably determining the effect of maternal ITP on neonatal morbidity.
